Mitoxantrone hydrochloride powder video
Mitoxantrone hydrochloride powder basic Characters
|Name:||Mitoxantrone hydrochloride powder|
|Color:||White or off white Crystalline powder|
Mitoxantrone hydrochloride powder in usage
Brand Name: Novantrone
Chemical Name: 1,4-dihydroxy-5,8-bis[[2-[2-hydroxyethyl)amino]ethyl]amino]9,10-anthracenedione dihydrochloride
Mitoxantrone hydrochloride powder Usage
Acute Myeloid Leukemia
A component of various chemotherapy regimens for remission induction in acute myeloid (myelogenous, nonlymphocytic) leukemia (AML, ANLL). AML includes acute promyelocytic, monocytic, myelomonocytic, megakaryoblastic, and erythroid leukemias.
Used in combination with other antineoplastic agents in consolidation therapy regimens following induction of complete remission.
Used as an alternative regimen for initial palliative treatment of advanced, symptomatic (i.e., painful) hormone-refractory prostate cancer (in combination with prednisone). Preferred first-line of treatment for hormone-refractory metastatic prostate cancer is docetaxel in combination with prednisone.
Multiple Sclerosis (MS)
Treatment of secondary (chronic) progressive, progressive-relapsing, or worsening relapsing-remitting MS. Used to reduce neurologic disability and/or frequency of relapse.
Has been studied in patients with the following disease patterns: Gradually increasing disability with or without superimposed clinical relapses (secondary progressive and progressive-relapsing subtypes) and clinical relapses resulting in stepwise increases in disability, with substantially abnormal neurologic status between relapses (worsening relapsing-remitting disease).
Not recommended for use in patients with primary progressive MS.
Should not be used for treatment of MS in patients with baseline LVEF <50% (seeMyocardial Toxicity in Boxed Warning). Generally not recommended for use in those with hepatic impairment (see Hepatic Impairment under Cautions) or in those with neutrophil count <1500/mm3.
Used as a component of combination chemotherapy regimens for treatment of low-grade non-Hodgkin’s lymphoma†.
What is the dosage of Mitoxantrone hydrochloride powder
Available as Mitoxantrone hydrochloride powder; dosage expressed in terms of mitoxantrone HCL powder .
Acute Myeloid Leukemia
12 mg/m2 daily on days 1–3 in combination with cytarabine 100 mg/m2 daily (as a continuous IV infusion over 24 hours) on days 1–7.
If antileukemic response to the first induction course is incomplete, a second induction course consisting of 2 days of mitoxantrone HCL powder (12 mg/m2 daily) and 5 days of cytarabine (100 mg/m2 daily) may be given.
If severe or life-threatening nonhematologic toxicity is observed during the initial induction course, withhold second induction course until toxicity resolves.
12 mg/m2 daily on days 1 and 2 in combination with cytarabine 100 mg/m2 daily (as a continuous IV infusion over 24 hours) on days 1–5. Administer initial consolidation course approximately 6 weeks after the final induction course; administer the second consolidation course generally 4 weeks after the initial course.
12–14 mg/m2 once every 21 days; give as an adjunct to corticosteroid therapy (e.g., prednisone 5 mg orally twice daily, hydrocortisone 40 mg orally daily). Some clinicians recommend discontinuance of mitoxantrone HCL powder (and continuation of corticosteroid therapy alone) in patients who are still responding after a cumulative mitoxantrone HCL powder dose of 140 mg/m2 due to risk of cardiac toxicity.
12 mg/m2 once every 3 months.
Maximum cumulative lifetime dose: 140 mg/m2.
Decreased clearance; dosage adjustment may be required, however, no specific dosage adjustment recommendations. (See Hepatic Impairment under Cautions.)
Dosage reduction not required.
Experience of Supervising Clinician
Administer only under the supervision of qualified clinicians experienced in the use of cytotoxic therapy.
Administer slowly into a freely running IV infusion solution. Do not administer by IM, sub-Q, intra-arterial, or intrathecal injection.
Severe local tissue necrosis if extravasation occurs. (See Local Effects under Cautions.)
Severe and sometimes irreversible neurotoxicity reported following intrathecal administration. (See Neurotoxicity under Cautions.)
Severe myelosuppression may occur. Generally avoid use in patients with baseline neutrophil count <1500/mm3, except for treatment of acute myeloid (myelogenous, nonlymphocytic) leukemia. Monitor hematologic status carefully. (See Hematologic Effects under Cautions.)
Possible cardiotoxicity and potentially fatal CHF during or months to years after therapy; risk increases with increasing cumulative dose.
Risk factors (history of or current cardiovascular disease, prior or concomitant irradiation to the mediastinal/pericardial area, previous therapy with other anthracyclines or anthracenediones, or concomitant use of other cardiotoxic drugs) may increase risk of cardiotoxicity. However, toxicity may occur regardless of whether cardiac risk factors are present. (See Cardiotoxicity under Cautions.)
Risk of CHF developing in cancer patients is estimated to be 2.6% at cumulative dose of up to 140 mg/m2.
Prior to initiation of therapy, evaluate all patients for cardiac signs/symptoms by history and physical examination and determine baseline left ventricular ejection fraction (LVEF) by echocardiogram or multigated radionuclide angiography (MUGA).
Do not initiate therapy in patients with multiple sclerosis if baseline LVEF is <50%.
In patients with multiple sclerosis, evaluate LVEF by echocardiogram or MUGA prior to each dose; do not administer additional doses if LVEF decreases to <50% or if a clinically important reduction in LVEF occurs.
Patients with multiple sclerosis should not receive cumulative dose >140 mg/m2.
Secondary Acute Myelogenous Leukemia (AML)
Secondary AML reported in patients treated with mitoxantrone HCL powder; risk of refractory secondary leukemias increases when anthracyclines are combined with other DNA-damaging antineoplastics, after extensive exposure to cytotoxic drugs, or when anthracycline doses have been escalated.(See Carcinogenicity under Cautions.)
Mitoxantrone hydrochloride Raw Powder
Min order 10grams.
The inquiry on normal quantity(Within 1kg) can be sent out in 12 hours after payment.
For larger order can be sent out in 3 working days after payment.
Mitoxantrone hydrochloride powder Marketing
To be provided in the coming future.
Does Mitoxantrone HCL powder Have Any Side Effects
Commonly reported side effects of mitoxantrone include: infection, upper respiratorytract infection, urinary tract infection, fungal infection, fungal skin infection, sepsis, alopecia, amenorrhea, cardiac arrhythmia, constipation, diarrhea, ecg abnormality, gastrointestinal hemorrhage, increased gamma-glutamyl transferase, leukopenia, menstrual disease, nausea, stomatitis, urine abnormality, abdominal pain, aphthous stomatitis, asthenia, burning sensation of gastrointestinal tract, cough, decreased hemoglobin, decreased white blood cell count, dyspnea, edema, epigastric pain, fatigue, fever,hematuria, hyperglycemia, hypocalcemia, hypokalemia, increased serum glucose,lymphocytopenia, mucositis, pharyngitis, rhinitis, stomach pain, thrombocytopenia, vomiting, weight gain, abnormal absolute neutrophil count, anorexia, malaise, and nailbedchanges. Other side effects include: pneumonia, renal failure syndrome, seizure,skininfection, anemia, back pain, granulocytopenia, headache, sinusitis, anxiety,arthralgia,conjunctivitis, depression, dyspepsia, heavy menstrual bleeding, hemorrhage, hypertension, hyponatremia, impotence, increased serum alanine aminotransferase, increased serum aspartate aminotransferase, ischemic heart disease, myalgia, pain, petechia, proteinuria, sterility, bruise, chills, diaphoresis, and ecchymoses. See below for acomprehensive list of adverse effects.
How to buy Mitoxantrone hydrochloride powder from AASraw
1.To contact us by our email inquiry system,or online skypecustomer service representative(CSR).
2.To provide us your inquired quantity and address.
3.Our CSR will provide you the quotation, payment term, tracking number, delivery ways and estimated arrival date(ETA).
4.Payment done and the goods will be sent out in 12 hours(For order within 10kg).
5.Goods received and give comments.
PRECAUTION AND DISCLAIMER:
This Material is Sold For Research Use Only. Terms of Sale Apply. Not for Human Consumption, nor Medical, Veterinary, or Household Uses.